Welcome to our dedicated page for Kymera Therapeutics SEC filings (Ticker: KYMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biotechnology company focused on targeted protein degradation (TPD). Through these filings, investors can review how Kymera reports its clinical progress, collaboration agreements, financing activities and corporate governance matters.
Kymera’s current reports on Form 8-K disclose material events such as clinical data presentations for KT-621, an investigational first-in-class oral STAT6 degrader in atopic dermatitis and asthma, and updates on KT-579, an oral IRF5 degrader for immune-mediated diseases. 8-K filings also describe key collaboration developments, including the IRAK4 degrader KT-485/SAR447971 with Sanofi for immuno-inflammatory diseases and an exclusive option and license agreement with Gilead Sciences covering an oral CDK2 molecular glue degrader program for potential use in breast cancer and other solid tumors.
Filings related to public offerings and capital structure outline Kymera’s underwritten offerings of common stock and pre-funded warrants, shelf registration statements on Form S-3 and associated underwriting agreements and registration rights agreements. These documents explain how the company raises capital to advance its pipeline of preclinical and clinical degrader programs and may detail potential milestone and royalty structures under collaboration arrangements.
Users can also consult SEC filings for information on Nasdaq listing details, including the KYMR ticker on The Nasdaq Global Market, as well as shareholder meeting results, board composition and executive transitions. Stock Titan’s platform pairs these filings with AI-powered summaries that highlight key terms, material developments and financial implications, helping readers navigate complex documents such as 8-Ks, registration statements and related exhibits more efficiently.
Kymera Therapeutics reported fourth-quarter and full-year 2025 results alongside a broad pipeline update. Collaboration revenue for 2025 was $39.2 million, down from $47.1 million in 2024, while higher R&D spending of $316.6 million and G&A of $68.2 million drove a wider annual net loss of $311.4 million versus $223.9 million a year earlier.
The company significantly strengthened its balance sheet by completing an underwritten equity offering with total gross proceeds of approximately $692 million, ending 2025 with about $1.6 billion in cash, cash equivalents and investments and projecting a cash runway into 2029.
Kymera highlighted progress for its KT-621 STAT6 degrader, including positive Phase 1b atopic dermatitis data, FDA Fast Track designation, and ongoing Phase 2b BROADEN2 (AD) and BREADTH (asthma) trials. It also began first-in-human dosing for KT-579, an IRF5 degrader in Phase 1, advanced partnered IRAK4 and CDK2 programs, and appointed experienced developer Neil Graham as Chief Development Officer.
Kymera Therapeutics CEO Nello Mainolfi reported a combination of option exercises and share sales on 2026-02-25. He exercised stock options for 30,000 shares at an exercise price of $2.08 per share, converting a derivative award into common stock.
On the same day he sold a total of 30,000 shares of common stock in open-market transactions at weighted average prices within disclosed ranges between $89.16 and $93.15 per share, pursuant to a pre-established Rule 10b5-1 trading plan dated September 6, 2024. After these transactions, he directly owned 666,195 shares of Kymera common stock.
KYMR issuer reports a proposed sale of 30,000 common shares. The Form 144 lists the 30,000-share sale as an exercise of stock options on 02/25/2026 to be sold in cash. The filing names Nello Mainolfi and also shows prior sales of 100,000 shares on 12/08/2025 and 30,000 shares on 12/31/2025.
Kymera Therapeutics director Pamela Esposito reported option exercises and share sales. She exercised stock options for 2,500 shares of common stock at $49.10 per share through a derivative conversion, from a fully vested and exercisable option grant.
On the same date, she sold 1,900 common shares at a weighted average price of $87.0579 and 600 shares at $88.10, in open-market transactions. According to the disclosure, these sales were executed under a Rule 10b5-1 trading plan dated September 17, 2025, which pre-arranges trades in advance.
KYMR: Pamela Esposito filed a Form 144 proposing the sale of 2,500 common shares related to an exercise of stock options for cash, with the transaction dated 02/20/2026. The filing lists prior sales in the past three months: 5,500 shares on 01/20/2026 for $373,521.20 and 27,563 shares on 12/17/2025 for $2,264,479.00.
Kymera Therapeutics, Inc. received an updated ownership report from several Wellington entities on a Schedule 13G/A. Wellington Management Group LLP and related entities report beneficial ownership of 4,412,933 shares of Kymera common stock, representing about 5.53% of the outstanding class.
The filing shows no sole voting or dispositive power, with voting and investment authority shared among Wellington affiliates and their advisory clients. The securities are held in the ordinary course of business, and Wellington states they are not held for the purpose of changing or influencing control of Kymera.
Kymera Therapeutics director Pamela Esposito reported multiple transactions in the company’s common stock on January 20, 2026. She exercised stock options for 3,000 shares at $31.2 and 2,500 shares at $49.1, receiving a total of 5,500 common shares. The filing then shows sales of 400 shares at $66.68, 4,900 shares at a weighted average price of $67.9888, and 200 shares at $68.52, reducing her directly held common stock to zero shares.
The stock option grants remain outstanding after these exercises. Esposito continues to hold 10,000 options with a $31.2 exercise price expiring on June 18, 2034, and 5,000 options with a $49.1 exercise price expiring on June 15, 2031. All option shares referenced are fully vested and exercisable, and the transactions were effected under a Rule 10b5-1 trading plan dated September 17, 2025.
A stockholder of Kymera Therapeutics (KYMR) filed a Form 144 notice to sell 5,500 common shares through Morgan Stanley Smith Barney LLC on or about 01/20/2026. The shares were acquired the same day by exercising stock options for cash, and the planned sale has an aggregate market value of $382,470.00. Kymera had 71,949,027 shares outstanding at the time referenced.
The filing also reports that, during the prior three months, there were Rule 10b5-1 sales for Pamela Esposito of 27,563 common shares on 12/17/2025, generating $2,264,479.00 in gross proceeds. By signing the notice, the seller represents they are not aware of any undisclosed material adverse information about Kymera’s operations.
Kymera Therapeutics, Inc. reported a preliminary estimate of approximately $1.6 billion in cash, cash equivalents and marketable securities as of December 31, 2025. These figures are unaudited, form part of its fourth-quarter and full-year 2025 results, and may change as the year-end audit is completed.
The company also provided a business update and outlined its key 2026 objectives and strategy to advance its leading portfolio of immunology programs in a press release furnished as Exhibit 99.1. Kymera plans to discuss these topics in meetings with participants at the 44th Annual J.P. Morgan Healthcare Conference.
FMR LLC and Abigail P. Johnson report beneficial ownership of 8,928,574.12 shares of Kymera Therapeutics Inc. common stock, representing 11.2% of the outstanding class as of the event date. FMR LLC has sole voting power over 8,921,331 shares and sole dispositive power over 8,928,574.12 shares, while Abigail P. Johnson has sole dispositive power over the same 8,928,574.12 shares and no voting power.
The securities are certified as being acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Kymera Therapeutics. The filing notes that one or more other persons have rights to dividends or sale proceeds for these shares, but no single such person has an interest exceeding five percent of the company’s common stock.